Genmab AS News - GE9 | Aktien Tradegate (DE)

Transactions in Connection with Share Buy-back Program

Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; April 22, 2025 – Genmab A/S (Nasdaq: GMAB). On...

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2025

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2025 Company Announcement Net sales of DARZALEX® in the first quarter...

Transactions in Connection with Share Buy-back Program

Transactions in Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; April 14, 2025 – Genmab A/S (Nasdaq: GMAB). On...

Genmab A/S Share Capital Reduction

Genmab A/S Share Capital Reduction Company Announcement COPENHAGEN, Denmark; April 10, 2025 – Genmab A/S (Nasdaq: GMAB) At Genmab A/S’ Annual...

Transactions In Connection with Share Buy-back Program

Transactions In Connection with Share Buy-back Program Company Announcement COPENHAGEN, Denmark; April 7, 2025 – Genmab A/S (Nasdaq: GMAB). On...

Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons Company...

TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer

TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer Media Release...

Transactions in connection with share buy-back program

Transactions in connection with share buy-back program Company Announcement COPENHAGEN, Denmark; March 31, 2025 – Genmab A/S (Nasdaq: GMAB). On...

TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy

TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer...

Genmab Announces Initiation of Share Buy-Back Program

Genmab Announces Initiation of Share Buy-Back Program Company Announcement Repurchase of up to 2.2 million shares with a maximum aggregate total...

Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc.

Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc. Company Announcement AbbVie Inc. files complaint...

Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer

Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer Media...

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons Company...

Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab

Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to...

Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38

Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38 Company Announcement Johnson & Johnson has decided that it will not...

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Genmab AS (GE9)

Professionelle Tools für Privatanleger.

GE9 Nachrichten

Transactions in Connection with Share Buy-back Program

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2025

Transactions in Connection with Share Buy-back Program

Genmab A/S Share Capital Reduction

Transactions In Connection with Share Buy-back Program

Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer

Transactions in connection with share buy-back program

TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy

Genmab Announces Initiation of Share Buy-Back Program

Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc.

Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab

Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38

GE9 Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Genmab AS (GE9) News

Genmab AS (GE9)

Professionelle Tools für Privatanleger.

GE9 Nachrichten

Transactions in Connection with Share Buy-back Program

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2025

Transactions in Connection with Share Buy-back Program

Genmab A/S Share Capital Reduction

Transactions In Connection with Share Buy-back Program

Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer

Transactions in connection with share buy-back program

TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy

Genmab Announces Initiation of Share Buy-Back Program

Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc.

Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab

Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38

GE9 Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Registrieren Sie sich für ein Konto unter ADVFN

Werbung entfernen